Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Impact of 18F-fluoroestradiol (FES) PET on treatment of ER+ HER2- metastatic breast cancer after first-line hormone therapy
2024-517400-11-00Phase 4Completed
- Sponsor
- GE HealthCare
- Start
- Oct 2024
- Modality
- Antibody-Radionuclide Conjugates → Antibody Conjugates → Antibody-Based Therapeutics, Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of fluoroestradiol f 18 in breast cancer, sponsored by GE HealthCare. Primary endpoint: Therapeutic impact of FES PET/CT. Started Oct 2024; status: completed.
02
Drugs
fluoroestradiol f 18
03
Conditions
breast cancer
Beyond the preview
Go deeper on 2024-517400-11-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-517400-11-00.